Fusion transcripts resulting from genomic translocations between RUNX1-RUNX1T1 in t(8;21) and CBFB-MYH11 in Inv(16), collectively referred to as CBF AML, have similar clinical outcomes, but the similarities and differences between the two entities have not been studied in detail. This evidence concerns the gene CBFB and acute myeloid leukemia.